THZ531 is primarily used in research settings to study and inhibit specific kinases, particularly those involved in cell cycle regulation and transcription. It is a potent and selective inhibitor of CDK12 and CDK13, which are crucial for the transcription of DNA into RNA. By inhibiting these kinases, THZ531 helps researchers understand their roles in cancer development and progression, as CDK12 and CDK13 are often dysregulated in various cancers. This compound is valuable in preclinical studies to explore potential therapeutic strategies for targeting cancers that rely on these kinases for survival and growth. Additionally, THZ531 is used to investigate the broader implications of transcriptional regulation in cellular processes and disease states. Its application in laboratory experiments aids in the development of targeted cancer therapies and provides insights into the molecular mechanisms underlying cancer biology.